MCOV B Stock Overview
Provides healthcare and diagnostic services in Poland, Sweden, and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 3/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Medicover AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 193.00 |
52 Week High | SEK 206.50 |
52 Week Low | SEK 118.30 |
Beta | 1.47 |
11 Month Change | 5.46% |
3 Month Change | -1.13% |
1 Year Change | 26.14% |
33 Year Change | -27.17% |
5 Year Change | 133.94% |
Change since IPO | 194.66% |
Recent News & Updates
Recent updates
Investors Appear Satisfied With Medicover AB (publ)'s (STO:MCOV B) Prospects
Apr 22Additional Considerations Required While Assessing Medicover's (STO:MCOV B) Strong Earnings
Apr 04Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet
Mar 05Medicover AB (publ)'s (STO:MCOV B) Intrinsic Value Is Potentially 31% Above Its Share Price
Feb 11Returns On Capital At Medicover (STO:MCOV B) Paint A Concerning Picture
Dec 20Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?
Dec 02Medicover's (STO:MCOV B) Returns On Capital Not Reflecting Well On The Business
Sep 12Medicover (STO:MCOV B) Has A Somewhat Strained Balance Sheet
Aug 21Is There An Opportunity With Medicover AB (publ)'s (STO:MCOV B) 37% Undervaluation?
Jun 12Medicover (STO:MCOV B) Will Want To Turn Around Its Return Trends
May 27Is Medicover (STO:MCOV B) Using Too Much Debt?
May 12Returns On Capital At Medicover (STO:MCOV B) Have Hit The Brakes
Feb 16Is Medicover (STO:MCOV B) Using Too Much Debt?
Jan 30Is Medicover AB (publ) (STO:MCOV B) Potentially Undervalued?
Dec 30Estimating The Fair Value Of Medicover AB (publ) (STO:MCOV B)
Dec 17Medicover (STO:MCOV B) Might Have The Makings Of A Multi-Bagger
Oct 30Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?
Oct 16Should You Think About Buying Medicover AB (publ) (STO:MCOV B) Now?
Sep 09Estimating The Intrinsic Value Of Medicover AB (publ) (STO:MCOV B)
Jul 25Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet
Jul 12Investors Met With Slowing Returns on Capital At Medicover (STO:MCOV B)
Jun 13At kr179, Is It Time To Put Medicover AB (publ) (STO:MCOV B) On Your Watch List?
May 29With EPS Growth And More, Medicover (STO:MCOV B) Is Interesting
Apr 20Medicover (STO:MCOV B) Could Easily Take On More Debt
Apr 08Shareholder Returns
MCOV B | SE Healthcare | SE Market | |
---|---|---|---|
7D | 4.1% | 1.7% | -2.6% |
1Y | 26.1% | 41.2% | 15.8% |
Return vs Industry: MCOV B underperformed the Swedish Healthcare industry which returned 37.9% over the past year.
Return vs Market: MCOV B exceeded the Swedish Market which returned 14.7% over the past year.
Price Volatility
MCOV B volatility | |
---|---|
MCOV B Average Weekly Movement | 3.5% |
Healthcare Industry Average Movement | 4.4% |
Market Average Movement | 5.6% |
10% most volatile stocks in SE Market | 12.0% |
10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: MCOV B has not had significant price volatility in the past 3 months.
Volatility Over Time: MCOV B's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | 45,000 | Fredrik Rågmark | www.medicover.com |
Medicover AB (publ) provides healthcare and diagnostic services in Poland, Sweden, and internationally. The company’s Healthcare services includes service outpatient and inpatient care; dental services; other services, including non-medical related services, such as sports memberships, benefit cards, and optics, as well as wellness services; hospital care; and preventive care. Its Diagnostic services comprise various tests, including allergy and autoimmune diagnostics, bacteriology, parasitology, biochemistry and immunochemistry, blood group diagnostics/transfusion medicine, tumour markers, clinical chemistry, cytology, haematology, histopathology, human genetics, hygiene, immunology and immunochemistry, infectious diseases, microbiology, molecular biology, and pharmacology/toxicology.
Medicover AB (publ) Fundamentals Summary
MCOV B fundamental statistics | |
---|---|
Market cap | SEK 28.98b |
Earnings (TTM) | SEK 264.53m |
Revenue (TTM) | SEK 21.88b |
109.5x
P/E Ratio1.3x
P/S RatioIs MCOV B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MCOV B income statement (TTM) | |
---|---|
Revenue | €1.91b |
Cost of Revenue | €1.52b |
Gross Profit | €394.70m |
Other Expenses | €371.60m |
Earnings | €23.10m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 30, 2024
Earnings per share (EPS) | 0.15 |
Gross Margin | 20.66% |
Net Profit Margin | 1.21% |
Debt/Equity Ratio | 124.4% |
How did MCOV B perform over the long term?
See historical performance and comparison